Researchers have offered a comprehensive understanding of the progression of multiple myeloma from a treatable condition to a high-risk disease by providing insights into its genetic diversity and subtypes, according to a recent study published by Skerget et al in Nature Genetics. Background. Multiple myeloma is the second most common...

Novel Insights Into Multiple Myeloma Progression

Reuters

(Reuters) -The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination treatment for a type of non-small cell lung cancer, setting up a challenge for AstraZeneca's blockbuster drug Tagrisso.

J&J's chemotherapy-free treatment for lung cancer gets US approval

Solly Chedid, MD, presents a patient case and provides clinical insights on approaching first-line therapy selection in patients with LR-MDS and moderate to severe anemia. Case: Frontline Use of Erythroid Maturating Agent (EMA): Luspatercept. Clinical Presentation:. 70-year-old man diagnosed 6 months ago with LR-MDS with multilineage dysplasia - moderate anemia...

Approach to 1L Therapy Selection in Lower-Risk MDS

Tampa, FL

Questions about multiple myeloma regarding treatment options, bone strength and other associated comorbidities were answered by an expert. Multiple myeloma is a rarer disease than other cancers, such as lung or breast cancer, an expert told CURE®. During the CURE® Educated Patient® Multiple Myeloma Summit, patients asked some questions about the disease.

Multiple Myeloma: 8 Frequently Asked Patient Questions

Experts in multiple myeloma sat down to discuss the use of bispecific antibodies and their impact in the space. The use of bispecific antibodies for patients with multiple myeloma was the latest topic of discussion during an Around the Practice® held during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Bispecific Antibodies Are Taking the Multiple Myeloma World by Storm

If you are an adult living with kidney disease and excess weight or obesity, you may be eligible to join a trial studying the impact of tirzepatide on kidney function. Trial Name: Tirzepatide Study of Renal Function in People With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease Using Multiparametric Magnetic Resonance Imaging (TREASURE-CKD)

New Trial Studying Tirzepatide for Chronic Kidney Disease

The Collaborative Ocular Oncology Group Study Number 2 (COOG2) prospectively validated a prognostic tool using positive RNA expression of Preferentially Expressed Antigen in Melanoma (PRAME)—a biomarker known to be effective in identifying type 1 uveal melanoma tumors at increased risk of metastasis—along with previously validated 15-gene expression profile (15-GEP) data for predicting metastasis in patients with certain types of uveal melanoma. While the integrated tool showed improved predictive accuracy over the use of individual predictors, additional studies are needed to evaluate its potential value for widespread use.

An Integrated 15-GEP/ Tool May Improve Uveal Melanoma Prognostication

For people who are at high risk of developing pancreatic cancer, regular imaging tests to monitor the pancreas may help detect the disease at an earlier stage than when pancreatic cancer is typically diagnosed in the general population, according to a new study. The study also suggests that detecting pancreatic...

Surveillance for People at High Risk of Pancreatic Cancer

A study published in the American Journal of Roentgenology (AJR) highlights the role of soft tissue, particularly when associated with vessel encasement and luminal narrowing, in raising suspicion for local recurrence (LR) after pancreatic ductal adenocarcinoma (PDAC) PDAC resection. “This AJR study provides insight into findings described in the Society...

New Soft Tissue on CT Suggests Local Recurrence After Pancreatic Cancer Resection

Chemotherapy is a type of cancer treatment that uses medications to kill fast-growing cancer cells. Depression may be one of the possible side effects of chemotherapy. Chemotherapy medications travel through the body and can mistakenly attack and damage healthy cells. This can leave a person with several side effects, which can be painful, change a person’s appearance, and affect their mood.

Chemotherapy and depression: Is there a connection?

Salt Lake City, UT

The drop improves vision by breaking up degraded protein complexes that cause lens clouding. Randall Olson, MD, corresponding author of the study, Moran Eye Center CEO and Distinguished Professor and Chair of the Department of Ophthalmology and Visual Sciences at the University of Utah, Salt Lake City, and colleagues reported that a novel eye drop (C-KAD, Livionex Inc.) has been formulated to treat early to moderate age-related cataracts. The drop improves vision by breaking up degraded protein complexes that cause lens clouding, which leads to cataracts and vision loss, when instilled in the eye.

Efficacy of novel eye drop to reverse cataracts after phase 1/2 study

Seattle, WA

Cancer Health

Lawrence Fong, MD’s research has focused on immunotherapy for more than 30 years. For many of those years, the new scientific director of the Immunotherapy Integrated Research Center at Fred Hutch Cancer Center considered immunotherapy — the practice of harnessing the body’s own immune system to fight cancer and other diseases — an idea whose time had not yet come.

How Immunotherapy Has Transformed Oncology

Health

Medically reviewed by Marla Anderson, MDMedically reviewed by Marla Anderson, MDNon-small cell lung cancer (NSCLC) is a type of cancer that begins in the tissues of the lungs. About 80-85% of all lung cancer cases in the United States are classified as NSCLC. NSCLC occurs when the cells that line the surface of the lung airways change and mutate. When these abnormal cells rapidly divide and multiply, they lead to cancer. The most common cause of NSCLC is smoking, with about 90% of lung cancer cases being related to tobacco smoke exposure. It is possible to be diagnosed with NSCLC if you...

What Causes Non-Small Cell Lung Cancer (NSCLC)?

Exposure to radiation during lung cancer treatment may increase future arrhythmia risk. Arrhythmia subtype varied by radiation dose and exposed cardiac structure. Exposure of certain cardiac structures to radiation during treatment of surgically inoperable or unresectable non-small cell lung cancer was associated with increased arrhythmia risk, researchers reported. The researchers...

Lung cancer radiotherapy exposes patients to arrhythmia risks based on factors such as dose

Immunotherapy May Facilitate Surgery and Improve Outcomes for Patients With High-Risk Liver Cancer. Patients with liver cancer who received immune checkpoint inhibitors (ICIs) before surgery—including those who would not have been eligible for surgery by conventional criteria—had similar outcomes to patients who received surgery upfront, according to results from a retrospective study published in Cancer Research Communications, a journal of the American Association for Cancer Research (AACR).

Immunotherapy Before Surgery May Improve Outcomes for Patients With Liver Cancer

Genome Medicine volume 16, Article number: 107 (2024) Cite this article. Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors (PARPi) are targeted therapies approved for homologous recombination repair (HRR)-deficient breast, ovarian, pancreatic, and prostate cancers. Since inhibition of PARP1 is sufficient to cause synthetic lethality in tumors with homologous recombination deficiency (HRD), PARP1 selective inhibitors such as saruparib (AZD5305) are being developed. It is expected that selective PARP1 inhibition leads to a safer profile that facilitates its combination with other DNA damage repair inhibitors. Here, we aimed to characterize the antitumor activity of AZD5305 in patient-derived preclinical models compared to the first-generation PARP1/2 inhibitor olaparib and to identify mechanisms of resistance.

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

T-DXd receives FDA breakthrough therapy designation for HR+/HER2-low breast cancer and real-world data confirms brexu-cel’s efficacy in relapsed/refractory B-cell ALL. A New AI-based study enrolls first patient, strengths and weakness in multiple myeloma treatment are examined, and tafasitamab combination scores in FL. Want to test your knowledge on the...

The Targeted Pulse: T-Dxd Received FDA Breakthrough Therapy Designation, Real-World Data Confirms Brexu-cel’s Impact, and More

Small cell lung cancer (SCLC) is a fast-growing cancer that develops in cells within the lung. A range of medical tests and procedures are available to help doctors diagnose SCLC and create an appropriate treatment plan. Lung cancer is a complex disease comprising various subtypes. A person who receives a...

How do doctors diagnose small cell lung cancer?

Opaganib was given orphan drug designation for the treatment of neuroblastoma in children, which is rare, but the most common infancy malignancy. Opaganib, a proprietary and investigational host-directed drug developed by Tel Aviv-based RedHill Biopharma, has been given orphan drug designation by FDA for treatment of neuroblastoma, a type of cancer that is the most common malignancy among infants, with a median age of 17 months at the time of diagnosis (1). RedHill announced the FDA decision in a press release on Aug. 26, 2024.

FDA Grants Orphan Drug Designation to RedHill’s Treatment for Neuroblastoma

The US Sun

A SCHOOLGIRL has been denied lifeline cancer therapy because NHS doctors say she’s ‘too old’ and ‘too young’. Faith Shone, 16, has leukaemia, which was caused by the heavy doses of chemotherapy she received two years ago to treat a leg tumour. Doctors say heavier doses of chemotherapy could cause her heart to fail, which […]

Teenager has to pay 70K for cancer treatment in NHS ‘blind spot’ or take offer of palliative care

NewsBreak

Efficacy and Treatment-Free Interval Support Earlier Use of CAR T in R/R Myeloma

Kenneth Shain, MD, PhD, discusses the rationale for giving chimeric antigen receptor (CAR) T-cell therapy in earlier lines of therapy for relapsed/refractory (R/R) multiple myeloma. Kenneth...

Efficacy and Treatment-Free Interval Support Earlier Use of CAR T in R/R Myeloma

Comments / 0